Orano Med unveils radiopharma manufacturing plant in Indianapolis

The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.

Jun 8, 2024 - 04:00

Orano Med unveils radiopharma manufacturing plant in Indianapolis

The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.

Read the original article

Tags:

Previous Article

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Private equity firm offers $5.8 billion buyout of hospital billing company R1 RCM

STAT+: Private equity firm offers $5.8 billion buyout o...

Feb 27, 2024

STAT+: Pharmalittle: FDA OKs Sage drug for postpartum depression; major U.S. health systems to offer Alzheimer’s drug

STAT+: Pharmalittle: FDA OKs Sage drug for postpartum d...

Aug 7, 2023

Opzelura by Incyte for Graft Versus Host Disease (GVHD)...

May 17, 2024